Syncona investment sells cancer study assets to AstraZeneca for $12m.
Life science investor Syncona said its investment Achilles Therapeutics has sold cancer study assets to AstraZeneca for $12m (£9.58m).
Syncona Limited NPV
27 December 2024 07:41:20
Source: Sharecast
The deal involves transferring of the commercial license of data and samples from Achilles’ TRACERx non-small cell lung cancer study to AstraZeneca, including samples and data.
Achilles added that it intended to cut an unspecified number of jobs and reduce the size of its board of directors.
Completion of this transaction signals the conclusion of the strategic review which was announced in September 2024.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.